SCHEMBL2935252

SCHEMBL2935252

CCOC(=O)c1cc(O)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 4/20 0.67
SLC6A2 P23975 1/20 0.67
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
HSP90AA1 P07900 1/20 0.49
MAPT P10636 1/20 0.49
CRHBP P24387 1/20 0.49
KMT2A Q03164 1/20 0.49
CRHR2 Q13324 1/20 0.49
TMEM97 Q5BJF2 5/20 0.47
BCL2L1 Q07817 1/20 0.46
ALOX5 P09917 1/20 0.46
DRD1 P21728 1/20 0.46
SIGMAR1 Q99720 1/20 0.45
MAOB P27338 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931976 0.86 BCL2L1 (0.49) P2RY14SLC6A2KDM4EMEN1MAPT
SCHEMBL30608333 0.83 MAOB (0.51) P2RY14SLC6A2KDM4EMEN1HSP90AA1
SCHEMBL26033093 0.82 P2RY14 (0.78) P2RY14SLC6A2TMEM97DRD1SIGMAR1
SCHEMBL2934955 0.82 BCL2L1 (0.47) P2RY14SLC6A2MEN1MAPTKMT2A
SCHEMBL2935754 0.82 P2RY14 (0.47) P2RY14SLC6A2KDM4EMEN1HSP90AA1
SCHEMBL22918399 0.81 P2RY14 (1.00) P2RY14SLC6A2TMEM97DRD1SIGMAR1
SCHEMBL3762664 0.80 P2RY14 (0.53) P2RY14TMEM97DRD1SIGMAR1
SCHEMBL2930789 0.80 TMEM97 (0.51) P2RY14TMEM97DRD1SIGMAR1
SCHEMBL2969954 0.80 P2RY14 (0.43) P2RY14SLC6A2KDM4EMEN1HSP90AA1
SCHEMBL3759380 0.79 TMEM97 (0.51) P2RY14TMEM97DRD1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298347-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY MERCK FROSST CANADA LTD (CA) 2010-11-25 US disclosed
EP-2229373-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY Merck Frosst Canada Ltd. (CA) 2010-09-22 EP disclosed
WO-2009070873-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY MERCK FROSST CANADA LTD. (CA) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298347-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY GPR119, GPR52, GPR35 P2RY14 423/4885SLC6A2 1169/4885KDM4E 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.